Literature DB >> 30747466

Prevalence of drug use among adults with intellectual disabilities compared with drug use in the general population.

Oddbjørn Hove1, Eva Biringer1, Odd E Havik2, Jörg Assmus3, Kirsten J Braatveit1, Silje Elisabeth Hasmo Holm4, Monica Hermann5.   

Abstract

PURPOSE: Individuals with intellectual disabilities (IDs) have more health problems, a poorer general health, and a shorter life expectancy than individuals in general. High rates of drug use in IDs have been reported. Despite the increasing interest in health problems in individuals with IDs, little is known about their drug use.
METHOD: Drug use in a community sample of adults with IDs (N = 593) was compared with dispensed drugs in a time-, age-, and region-matched comparison group of adults in Western Norway (N = 289 325). A logistic regression model was employed by using the main group effect to describe and analyze the differences between the ID sample and the comparison sample and by using the interaction term (group × age) to describe the rate change differences from the reference age (18-30 years) between the two groups.
RESULTS: Total drug use in the ID sample was 62% compared with 50% in the reference sample (P = 0.0001). The high prevalence of drugs for the nervous system (ATC N) in the ID sample (50%) explained the difference. From age 51 and over, the increase in the drug use rate for the cardiovascular disease was significantly lower in the ID sample than in the reference sample (P value range: 0.002-0.019).
CONCLUSIONS: Adults with IDs use more drugs than adults in general. However, the findings showed lower rates of drug use in the ID sample than in the general population for drugs targeting diseases that are the leading causes of death in individuals with IDs.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cardiovascular diseases; intellectual disabilities; pharmacoepidemiology; psycholeptics

Mesh:

Year:  2019        PMID: 30747466     DOI: 10.1002/pds.4741

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  2 in total

1.  Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database.

Authors:  Steven R Erickson; Tanima Basu; Michael P Dorsch; Neil Kamdar
Journal:  Ann Pharmacother       Date:  2020-04-27       Impact factor: 3.154

Review 2.  Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review.

Authors:  Neasa Kelly; Andrew Kilmartin; Kevin Lannon; Caren Lee; Rory McLoughlin; Lara Mulvanny; Omnyiah Mohamed; Mairead Treacy; Karen Rossi; Juliette O'Connell
Journal:  Eur J Clin Pharmacol       Date:  2022-08-31       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.